Akebia Therapeutics (AKBA) Set to Release Quarterly Earnings on Thursday

Akebia Therapeutics (NASDAQ:AKBA) is expected to announce its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect Akebia Therapeutics to announce earnings of ($0.0360) per share and revenue of $46.94 million for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:00 AM ET.

Akebia Therapeutics (NASDAQ:AKBA) last announced its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($0.02) EPS for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.02. Akebia Therapeutics had a negative net margin of 13.54% and a negative return on equity of 88.88%. The firm had revenue of $49.13 million during the quarter, compared to analyst estimates of $48.85 million. On average, analysts expect Akebia Therapeutics to post ($0.14) EPS for the current fiscal year and ($0.27) EPS for the next fiscal year.

Akebia Therapeutics Price Performance

AKBA opened at $0.73 on Wednesday. The company has a debt-to-equity ratio of 0.99, a current ratio of 1.43 and a quick ratio of 1.35. The firm has a 50 day moving average price of $0.84 and a 200-day moving average price of $1.14. Akebia Therapeutics has a twelve month low of $0.54 and a twelve month high of $2.15.

Wall Street Analyst Weigh In

A number of research firms have commented on AKBA. Wall Street Zen raised shares of Akebia Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday. Westpark Capital initiated coverage on shares of Akebia Therapeutics in a research note on Tuesday, September 8th. They set a “buy” rating and a $4.50 target price for the company. Zacks Research raised Akebia Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 7th. Leerink Partners cut Akebia Therapeutics from an “outperform” rating to a “market perform” rating and set a $1.00 price target on the stock. in a report on Friday, August 7th. Finally, Weiss Ratings downgraded Akebia Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, October 2nd. Four research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $3.90.

Akebia Therapeutics Company Profile

Akebia Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing therapies for patients with kidney disease and related conditions. The company’s primary areas of interest include anemia associated with chronic kidney disease (CKD), iron deficiency, and disorders involving mineral metabolism.

Akebia’s key product is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase inhibitor designed to stimulate the body’s natural production of erythropoietin and support red blood cell formation.